Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.66 | N/A | -67.93% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.66 | N/A | -67.93% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter but emphasized their commitment to pipeline development. They did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the EPS miss.
PTC Therapeutics reported a significant EPS miss, which typically raises concerns among investors. However, the stock saw a slight increase of 0.3%, likely due to investors focusing on the company's long-term pipeline rather than short-term earnings. The lack of revenue guidance suggests uncertainty in the near term, but management's commitment to their projects may have reassured some investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WELLTOWER INC REIT
Jul 31, 2023